Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.

Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R

Bone1 Aug 2006Cited by 41 (Europe PMC)

PMID16884968DOI10.1016/j.bone.2006.06.007PepBankPUB-16884968

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In compliant osteoporotic postmenopausal women, 91% receiving teriparatide 20 microg/day attained a lumbar spine BMD increase of at least 3%.
In plain wordsIn compliant women with osteoporosis, 91% receiving teriparatide 20 microg/day gained at least 3% spinal bone density.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableLumbar spine BMD responders at 20 microg/day
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/day · 18 monthsAs given in this study (human).
Measurements
Lumbar spine BMD responders
91%
teriparatide 20 microg/day at 18 months
Source sentences
Summary
According to the LSC criteria, 91% of the teriparatide 20 microg/day group and 94% of the teriparatide 40 microg/day group were lumbar spine BMD responders at 18 months in the Fracture Prevention Trial.
5 context sentences(design, population, supporting numbers)
Summary · context
The focus of this analysis was to determine what percentage of women attained a lumbar spine BMD response to teriparatide that equaled or exceeded the least significant change (LSC) value of 3%.
Summary · context
Data from three clinical trials involving postmenopausal women with osteoporosis were examined.
Summary · context
The Fracture Prevention Trial was a double-blinded, placebo-controlled clinical trial examining the safety and efficacy of teriparatide 20 and 40 microg/day.
Summary · context
The other two trials were double-blinded, head-to-head comparisons of alendronate 10 mg/day and teriparatide 20 or 40 microg/day, respectively.
Summary · context
Only treatment-compliant women who had lumbar spine BMD measurements at all specified time points in these trials were included.
Report a problemFND-1688496801
02HumanNon-randomized trialEfficacy outcome
In compliant osteoporotic postmenopausal women, 94% receiving teriparatide 40 microg/day attained a lumbar spine BMD increase of at least 3%.
In plain wordsIn compliant women with osteoporosis, 94% receiving teriparatide 40 microg/day gained at least 3% spinal bone density.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableLumbar spine BMD responders at 40 microg/day
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg/day · 18 monthsAs given in this study (human).
Measurements
Lumbar spine BMD responders
94%
teriparatide 40 microg/day at 18 months
Source sentences
Summary
According to the LSC criteria, 91% of the teriparatide 20 microg/day group and 94% of the teriparatide 40 microg/day group were lumbar spine BMD responders at 18 months in the Fracture Prevention Trial.
5 context sentences(design, population, supporting numbers)
Summary · context
The focus of this analysis was to determine what percentage of women attained a lumbar spine BMD response to teriparatide that equaled or exceeded the least significant change (LSC) value of 3%.
Summary · context
Data from three clinical trials involving postmenopausal women with osteoporosis were examined.
Summary · context
The Fracture Prevention Trial was a double-blinded, placebo-controlled clinical trial examining the safety and efficacy of teriparatide 20 and 40 microg/day.
Summary · context
The other two trials were double-blinded, head-to-head comparisons of alendronate 10 mg/day and teriparatide 20 or 40 microg/day, respectively.
Summary · context
Only treatment-compliant women who had lumbar spine BMD measurements at all specified time points in these trials were included.
Report a problemFND-1688496802
03HumanNon-randomized trialEfficacy outcome
In compliant osteoporotic women, lumbar spine BMD response rates were higher with teriparatide 20 microg than alendronate at 18 months.
In plain wordsIn compliant women with osteoporosis, spinal bone density response was more common with teriparatide 20 microg than alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD responders versus alendronate at 20 microg/day
Study
n: not reported in source
Comparator
Alendronate 10 mg/day
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/day · 18 monthsAs given in this study (human).
Measurements
Lumbar spine BMD responders
94%
teriparatide
Lumbar spine BMD responders
75%
alendronate
Source sentences
Summary
In the teriparatide 20 microg/alendronate head-to-head trial, 94% of women receiving teriparatide had a lumbar spine BMD response that equaled or exceeded the 3% criterion at 18 months compared to 75% of those receiving alendronate 10 mg/day (p < 0.01).
4 context sentences(design, population, supporting numbers)
Summary · context
Data from three clinical trials involving postmenopausal women with osteoporosis were examined.
Summary · context
The Fracture Prevention Trial was a double-blinded, placebo-controlled clinical trial examining the safety and efficacy of teriparatide 20 and 40 microg/day.
Summary · context
The other two trials were double-blinded, head-to-head comparisons of alendronate 10 mg/day and teriparatide 20 or 40 microg/day, respectively.
Summary · context
Only treatment-compliant women who had lumbar spine BMD measurements at all specified time points in these trials were included.
Report a problemFND-1688496803
04HumanNon-randomized trialEfficacy outcome
In compliant osteoporotic women, lumbar spine BMD response rates were higher with teriparatide 40 microg/day than alendronate at 12 months.
In plain wordsIn compliant women with osteoporosis, spinal bone density response was more common with teriparatide 40 microg/day than alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD responders versus alendronate at 40 microg/day
Study
n: not reported in source
Comparator
Alendronate 10 mg/day
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg/day · 12 monthsAs given in this study (human).
Measurements
Lumbar spine BMD responders
92%
teriparatide
Lumbar spine BMD responders
69%
alendronate
Source sentences
Summary
In the teriparatide 40 microg/day group of the other head-to-head trial, 92% of women achieved the 3% criterion for the lumbar spine at 12 months compared to 69% of those receiving alendronate 10 mg/day (p < 0.01).
4 context sentences(design, population, supporting numbers)
Summary · context
Data from three clinical trials involving postmenopausal women with osteoporosis were examined.
Summary · context
The Fracture Prevention Trial was a double-blinded, placebo-controlled clinical trial examining the safety and efficacy of teriparatide 20 and 40 microg/day.
Summary · context
The other two trials were double-blinded, head-to-head comparisons of alendronate 10 mg/day and teriparatide 20 or 40 microg/day, respectively.
Summary · context
Only treatment-compliant women who had lumbar spine BMD measurements at all specified time points in these trials were included.
Report a problemFND-1688496804
05HumanNon-randomized trialEfficacy outcome
In compliant osteoporotic women, hip BMD response meeting the 3% threshold was more frequent with teriparatide than placebo.
In plain wordsIn compliant women with osteoporosis, hip bone density response was more common with teriparatide than placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseHip BMD responders versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Although the percentage of teriparatide-treated women with a hip BMD response that met the 3% criterion was significantly greater than for placebo,
4 context sentences(design, population, supporting numbers)
Summary · context
Data from three clinical trials involving postmenopausal women with osteoporosis were examined.
Summary · context
The Fracture Prevention Trial was a double-blinded, placebo-controlled clinical trial examining the safety and efficacy of teriparatide 20 and 40 microg/day.
Summary · context
The other two trials were double-blinded, head-to-head comparisons of alendronate 10 mg/day and teriparatide 20 or 40 microg/day, respectively.
Summary · context
Only treatment-compliant women who had lumbar spine BMD measurements at all specified time points in these trials were included.
Report a problemFND-1688496807
06HumanNon-randomized trialEfficacy outcome
In compliant osteoporotic women, hip BMD response rates did not differ significantly between teriparatide 20 microg/day and alendronate 10 mg/day.
In plain wordsIn compliant women with osteoporosis, hip bone density response rates were similar with teriparatide 20 microg/day and alendronate 10 mg/day.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeHip BMD responders versus alendronate
Study
n: not reported in source
Comparator
Alendronate 10 mg/day
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/dayAs given in this study (human).
Source sentences
Summary
there was no significant difference between the percentage of teriparatide 20 microg/day and alendronate 10 mg/day responders in the comparison trial.
4 context sentences(design, population, supporting numbers)
Summary · context
Data from three clinical trials involving postmenopausal women with osteoporosis were examined.
Summary · context
The Fracture Prevention Trial was a double-blinded, placebo-controlled clinical trial examining the safety and efficacy of teriparatide 20 and 40 microg/day.
Summary · context
The other two trials were double-blinded, head-to-head comparisons of alendronate 10 mg/day and teriparatide 20 or 40 microg/day, respectively.
Summary · context
Only treatment-compliant women who had lumbar spine BMD measurements at all specified time points in these trials were included.
Report a problemFND-1688496808
07HumanObservational studyEfficacy outcome
In teriparatide-treated lumbar spine BMD nonresponders, median PINP change exceeded the least significant change of 10 microg/L.
In plain wordsIn women receiving teriparatide without a spinal bone density response, median PINP change exceeded 10 microg/L.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePINP change in lumbar spine BMD nonresponders
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Measurements
Median PINP change
> 10 microg/L
lumbar spine BMD nonresponders
Source sentences
Summary
However, the median 3-month PINP change in lumbar spine BMD nonresponders still exceeded the LSC value of 10 microg/L.
5 context sentences(design, population, supporting numbers)
Summary · context
The median 3-month change in amino-terminal extension peptide of procollagen type 1 [PINP] in women who had a lumbar spine BMD response to teriparatide at 18 months was larger than in women who did not have a lumbar spine BMD response.
Summary · context
Data from three clinical trials involving postmenopausal women with osteoporosis were examined.
Summary · context
The Fracture Prevention Trial was a double-blinded, placebo-controlled clinical trial examining the safety and efficacy of teriparatide 20 and 40 microg/day.
Summary · context
The other two trials were double-blinded, head-to-head comparisons of alendronate 10 mg/day and teriparatide 20 or 40 microg/day, respectively.
Summary · context
Only treatment-compliant women who had lumbar spine BMD measurements at all specified time points in these trials were included.
Report a problemFND-1688496806

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

08HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
Among teriparatide-treated women, median PINP change was larger in lumbar spine BMD responders than nonresponders.
In plain wordsIn women receiving teriparatide, PINP change was linked to spinal bone density response and was larger in responders than nonresponders.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePINP change in lumbar spine BMD responders versus nonresponders
Study
n: not reported in source
Comparator
Teriparatide lumbar spine BMD nonresponders
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The median 3-month change in amino-terminal extension peptide of procollagen type 1 [PINP] in women who had a lumbar spine BMD response to teriparatide at 18 months was larger than in women who did not have a lumbar spine BMD response.
4 context sentences(design, population, supporting numbers)
Summary · context
Data from three clinical trials involving postmenopausal women with osteoporosis were examined.
Summary · context
The Fracture Prevention Trial was a double-blinded, placebo-controlled clinical trial examining the safety and efficacy of teriparatide 20 and 40 microg/day.
Summary · context
The other two trials were double-blinded, head-to-head comparisons of alendronate 10 mg/day and teriparatide 20 or 40 microg/day, respectively.
Summary · context
Only treatment-compliant women who had lumbar spine BMD measurements at all specified time points in these trials were included.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1688496805
09HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
Among teriparatide-treated women, lumbar spine BMD responders and nonresponders had similar baseline characteristics.
In plain wordsIn women receiving teriparatide, baseline characteristics were similar in spinal bone density responders and nonresponders.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBaseline characteristics in lumbar spine responders versus nonresponders
Study
n: not reported in source
Comparator
Teriparatide lumbar spine BMD nonresponders
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The baseline characteristics of teriparatide lumbar spine responders and nonresponders were similar.
4 context sentences(design, population, supporting numbers)
Summary · context
Data from three clinical trials involving postmenopausal women with osteoporosis were examined.
Summary · context
The Fracture Prevention Trial was a double-blinded, placebo-controlled clinical trial examining the safety and efficacy of teriparatide 20 and 40 microg/day.
Summary · context
The other two trials were double-blinded, head-to-head comparisons of alendronate 10 mg/day and teriparatide 20 or 40 microg/day, respectively.
Summary · context
Only treatment-compliant women who had lumbar spine BMD measurements at all specified time points in these trials were included.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1688496809

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.